|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
A New York-based hedge fund which owns 17 percent of Acorda Therapeutics Inc called on the U.S. developer of drugs targeting neurological disorders on Monday to explore a sale of the company, according to a regulatory filing with the U.S. Securities and Exchange Commission. Pressure on Acorda to pursue a sale comes after a judge last March struck down key patents of its multiple sclerosis drug Ampyra, which accounts for almost all of its revenue. This means Ampyra could face generic competition as early as next year.
LONDON, UK / ACCESSWIRE / July 26, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for NeuroDerm Ltd (NASDAQ: NDRM ), following which we have published ...
Japan's Nikkei share average edged down on Tuesday in choppy trade as investors braced for the outcome of the U.S. Federal Reserve's policy meeting which begins later in the day. The Nikkei ended 0.1 percent lower at 19,955.20 after trading in positive territory. "The equity market is on hold at the moment, waiting for the Federal Open Market Committee (FOMC) outcome.
Japan's Nikkei share average inched up on Tuesday as the market found its footing following the previous day's fall, although the index was confined in a narrow range ahead of the U.S. Federal Reserve's policy meeting. The Nikkei was up 0.05 percent at 19,987.25, drawing mild support as the yen pulled back from a five-week high versus the dollar. Much investor focus was on the Fed's two-day meeting due to start later on Tuesday, and its potential impact on financial markets.
TOKYO/TEL AVIV, July 24 (Reuters) - Japan's Mitsubishi Tanabe Pharma Corp has agreed to buy Israeli drug maker Neuroderm for $1.1 billion in cash as part of a strategy to grow its business in the United States. The Japanese drugmaker said on Monday it was particularly attracted by Neuroderm's Parkinson's disease drug that is in advanced clinical trials in the United States and Europe and is expected to go on sale in the 2019 financial year. It said the deal was intended to help it "achieve its U.S. sales target of 80 billion yen" ($722 million) by its 2020 financial year.
NEW YORK, NY / ACCESSWIRE / June 1, 2017 / NeuroDerm was one of the biggest winners on the NASDAQ despite any significant news, aside from traders perhaps anticipating next week's 21 st International Congress ...